Burden of advanced Non-small Cell lung Cancer in the Catalan Health Service (CatSalut)

Abstract

Introduction: Advance non-small cell lung cancer (NSCLC) is a disease with a high clinical and economic burden for healthcare systems. It exists few studies on the management costs of NSCLC patients. The main objective of this study was to identify healthcare resource consumption and costs related to management of advanced NSCLC in the context of the Catalan Health Service (CatSalut). Methodology: A systematic literature review (SLR) was performed to identify resource use for NSCLC management. Additionally was completed with observational data and expert’s opinion. Pharmacoeconomics evaluation was a costs analysis using a decision modelling for diagnosis and clinical - therapeutic pathway. for a time horizon of one year. Results: Total costs for advanced NSCLC patients (N= 4.026) would account for 141.054.270€/year: 9% for diagnostic and 91% for clinical - therapeutic management. The main cost driver could be associated to anticancer drugs (44-61% of the total medical costs) across the different line of treatment: 46.403.510€ in first line, 19.980.440€ in second line and 6.517.901€ in third line and after. The overall healthcare cost for advanced NSCLC could result in 1,65% of the total public health budget in Catalonia. Conclusion: Advanced NSCLC management could increase in healthcare spending. The identification of an appropriate therapeutic pathway, resource use and costs could support healthcare policies and interventions to guarantee an adequate and efficient disease management ensuring care accessibility for all patients. Keywords: Advanced Non-small cell lung cancer, NSCLC, diagnosis and disease management, cost of disease, resource use, CatSalut.